Statements (84)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Roche_Pharma
|
| gptkbp:activities |
neuraminidase inhibitor
|
| gptkbp:appointed_by |
oral capsule
oral suspension |
| gptkbp:approves |
gptkb:1999
gptkb:FDA |
| gptkbp:availability |
widely available
|
| gptkbp:brand |
gptkb:Tamiflu
|
| gptkbp:category |
gptkb:unknown
gptkb:C |
| gptkbp:clinical_trial |
Phase III
Phase III trials prophylaxis of influenza acute influenza started within 48 hours of symptom onset |
| gptkbp:contraindication |
renal impairment
hypersensitivity to oseltamivir |
| gptkbp:developed_by |
gptkb:Roche
gptkb:Gilead_Sciences |
| gptkbp:dosage_form |
gptkb:beer
oral suspension 75 mg twice daily |
| gptkbp:duration |
10 days
5 days |
| gptkbp:effective_date |
gptkb:1999
|
| gptkbp:form |
gptkb:beer
gptkb:item |
| gptkbp:formulation |
capsule for adults
suspension for children |
| https://www.w3.org/2000/01/rdf-schema#label |
Tamiflu
|
| gptkbp:indication |
prevention of influenza
treatment of influenza in adults treatment of influenza in children |
| gptkbp:ingredients |
gptkb:oseltamivir
C16 H28 N2 O4 S |
| gptkbp:interacts_with |
gptkb:warfarin
live attenuated influenza vaccine probenecid |
| gptkbp:invention |
gptkb:2016
patented |
| gptkbp:is_atype_of |
J05 A H02
|
| gptkbp:is_available_in |
liquid form
tablet form |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_effective_against |
common cold
reduces duration of flu symptoms reduces duration of symptoms reduces risk of complications |
| gptkbp:is_used_for |
treatment of influenza
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Roche
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe Tamiflu brand name |
| gptkbp:name |
Essential Medicines
|
| gptkbp:previous_name |
gptkb:oseltamivir_phosphate
|
| gptkbp:price |
varies by country
|
| gptkbp:provides_information_on |
WHO recommendations
CDC recommendations |
| gptkbp:requires |
gptkb:theorem
prescription only |
| gptkbp:safety_features |
Category C
|
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
dizziness
headache nausea allergic reactions vomiting diarrhea neuropsychiatric events |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
patients with severe renal impairment
children under 2 years pregnant women without consultation patients with severe liver disease nursing mothers without consultation patients with hypersensitivity reactions |
| gptkbp:treatment |
within 48 hours of symptom onset
|
| gptkbp:weight |
312.48 g/mol
|